Data as of Sep 19
| +0.0794 / +8.62%|
The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 3.50, with a high estimate of 4.00 and a low estimate of 3.00. The median estimate represents a +250.00% increase from the last price of 1.00.
The current consensus among 2 polled investment analysts is to Buy stock in ImmunoCellular Therapeutics Ltd. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.